相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The mTOR Signalling Pathway in Human Cancer
Helena Populo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma
Natalie Cook et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy
Roeland F. de Wilde et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
Lise Willems et al.
CURRENT ONCOLOGY REPORTS (2012)
First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
Jonathan R. Strosberg et al.
CANCER (2011)
mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours
Atsuko Kasajima et al.
ENDOCRINE-RELATED CANCER (2011)
Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors
Theodore Liakakos et al.
FUTURE ONCOLOGY (2011)
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
Seth A. Wander et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Surgical treatment of gastrointestinal neuroendocrine tumors
Volker Fendrich et al.
LANGENBECKS ARCHIVES OF SURGERY (2011)
TRANSLATIONAL MEDICINE Cancer lessons from mice to humans
David Tuveson et al.
NATURE (2011)
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
New Epigenetic Drivers of Cancers
Simon J. Elsaesser et al.
SCIENCE (2011)
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Christopher M. Heaphy et al.
SCIENCE (2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Yuchen Jiao et al.
SCIENCE (2011)
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
N. C. Turner et al.
BRITISH JOURNAL OF CANCER (2010)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors
Takashi Shida et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Distinct Factors Control Histone Variant H3.3 Localization at Specific Genomic Regions
Aaron D. Goldberg et al.
CELL (2010)
Evaluation of the Combination 5-Fluorouracil, Dacarbazine, and Epirubicin in Patients With Advanced Well-Differentiated Neuroendocrine Tumors
Thomas Walter et al.
CLINICAL COLORECTAL CANCER (2010)
MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases
Vincenzo Corbo et al.
ENDOCRINE-RELATED CANCER (2010)
Pasireotide for the treatment of Cushing's disease
Giorgio Arnaldi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer
Sebastien Albert et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Dramatic efficacy of chemotherapy with 5-fluoro-uracile and dacarbazine in a patient with metastatic glucagonoma and cardiac insufficiency
L. de Mestier et al.
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE (2010)
The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3
Pascal Drane et al.
GENES & DEVELOPMENT (2010)
ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells
Lee H. Wong et al.
GENOME RESEARCH (2010)
Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis
Christopher W. Chiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
Edoardo Missiaglia et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Everolimus: A Proliferation Signal Inhibitor with Clinical Applications in Organ Transplantation, Oncology, and Cardiology
Steven Gabardi et al.
PHARMACOTHERAPY (2010)
O-6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke et al.
CLINICAL CANCER RESEARCH (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Brief Report: Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449.
Charles M. Rudin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
T. R. Halfdanarson et al.
ANNALS OF ONCOLOGY (2008)
Menin, Histone H3 Methyltransferases, and Regulation of Cell Proliferation: Current Knowledge and Perspective
Xinjiang Wu et al.
CURRENT MOLECULAR MEDICINE (2008)
Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors
David C. Metz et al.
GASTROENTEROLOGY (2008)
Multiple endocrine neoplaslia type 1 (MEN 1): Analysis of 1336 mutations reported in the first decade following identification of the gene
Manuel C. Lemos et al.
HUMAN MUTATION (2008)
DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor
Lynn-Kristin Bracht et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda®) monotherapy
Gregor Fuerstenberger et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
Sara Ekeblad et al.
CLINICAL CANCER RESEARCH (2007)
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Emilio Bajetta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers
Georg Feldmann et al.
CANCER RESEARCH (2007)
The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells
Kathrin Zitzmann et al.
NEUROENDOCRINOLOGY (2007)
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Thuy L. Phung et al.
CANCER CELL (2006)
Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1
MA Kouvaraki et al.
WORLD JOURNAL OF SURGERY (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
Estimating the cost of new drug development: Is it really $802 million?
CP Adams et al.
HEALTH AFFAIRS (2006)
Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas
F Triponez et al.
ANNALS OF SURGERY (2006)
Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1
L Thomas-Marques et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
MH Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Targeted modulation of MGMT: Clinical implications
LL Liu et al.
CLINICAL CANCER RESEARCH (2006)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
GV Thomas et al.
NATURE MEDICINE (2006)
Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization
F Panzuto et al.
ENDOCRINE-RELATED CANCER (2005)
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas
MA Kouvaraki et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Clinical pharmacokinetics of everolimus
GI Kirchner et al.
CLINICAL PHARMACOKINETICS (2004)
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors
AD McCollum et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2004)
EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia
EJ Wamsteker et al.
GASTROINTESTINAL ENDOSCOPY (2003)
Effect of rifampin on apparent clearance of everolimus
JM Kovarik et al.
ANNALS OF PHARMACOTHERAPY (2002)
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282
RK Ramanathan et al.
ANNALS OF ONCOLOGY (2001)
Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells
A Perren et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
